Subsequent molecular docking demonstrated that the top ten compounds of FLD presented desirable binding energy with CASP3, ALB, and MAPK1, further revealing the potentional mechanism of FLD's action on NAFLD. The gene discussed is MAPK1; the disease is metabolic dysfunction-associated steatotic liver disease.